130 related articles for article (PubMed ID: 36408660)
1. Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
Hogenhout R; Osses DF; Alberts AR; Buizer-Rijksen HG; Remmers S; Roobol MJ
BJU Int; 2023 May; 131(5):596-601. PubMed ID: 36408660
[TBL] [Abstract][Full Text] [Related]
2. Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic.
Osses DF; Alberts AR; Bausch GCF; Roobol MJ
Transl Androl Urol; 2018 Feb; 7(1):27-33. PubMed ID: 29594017
[TBL] [Abstract][Full Text] [Related]
3. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.
Hagens MJ; Stelwagen PJ; Veerman H; Rynja SP; Smeenge M; van der Noort V; Roeleveld TA; van Kesteren J; Remmers S; Roobol MJ; van Leeuwen PJ; van der Poel HG
World J Urol; 2023 Jan; 41(1):13-18. PubMed ID: 36245015
[TBL] [Abstract][Full Text] [Related]
4. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
5. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract][Full Text] [Related]
6. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
[TBL] [Abstract][Full Text] [Related]
10. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
[TBL] [Abstract][Full Text] [Related]
11. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
12. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Witjes JA; van Melick HHE; Somford DM
BJU Int; 2023 Mar; 131(3):313-320. PubMed ID: 35993590
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator.
de Vos II; Drost FH; Bokhorst LP; Alberts AR; van Gelder M; Herman EM; Boswinkel WD; Bangma CH; Roobol MJ
Transl Androl Urol; 2023 Feb; 12(2):241-248. PubMed ID: 36915892
[TBL] [Abstract][Full Text] [Related]
15. Detection of clinically significant cancer in the anterior prostate by transperineal biopsy.
Cowan T; Baker E; McCray G; Reeves F; Houlihan K; Johns-Putra L
BJU Int; 2020 Sep; 126 Suppl 1():33-37. PubMed ID: 32463977
[TBL] [Abstract][Full Text] [Related]
16. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
17. Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy.
Remmers S; Nieboer D; Rijstenberg LL; Hansum T; van Leenders GJLH; Roobol MJ
Eur Urol Open Sci; 2022 Feb; 36():19-22. PubMed ID: 34977692
[TBL] [Abstract][Full Text] [Related]
18. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
[TBL] [Abstract][Full Text] [Related]
19. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
